Precision medicine study for people with certain cancers in Ontario
Observes people with breast, colorectal, pancreas, kidney, prostate or ovary cancer.
Plain-language title generated from the registry record
Registry title: Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Key facts
- Where
- Kingston, Ottawa, and Toronto, CanadaSee the 3 sites
Where in Canada
- Kingston Health Sciences CentreKingston, CanadaTaking people
- Ottawa Health Research InstituteOttawa, CanadaNot yet recruiting
- Princess Margaret Cancer CentreToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT05403177
- Record updated
- 10 June 2026
- Original description
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patientsRead full original descriptionShow less
Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Inclusion: Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy; All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:; Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1); Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization; Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling; Participating patients must agree to share their anonymized clinical and genomic data.
Exclusion: None.